RT
Rinascera Therapeutics, Inc.
SEC filingBiotechnology · Boston, MA
Amount raised$2.5Msold at filing
Total offering$2.5M
Investors in the raise3count reported to the SEC
FiledOct 8, 2025first sale Sep 12, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Nichola EliovitsExecutive Officer, Director
Max DawsonExecutive Officer
Daniel YadegarDirector
Karl BeutnerExecutive Officer, Director
Executive officers, directors and promoters as listed on the Form D.